HER2+/HR+ Breast Cancer
1 clinical trials · Condition
◉ Watch HER2+/HR+ Breast Cancer
| Record | Firm | Date |
|---|---|---|
| A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+/HR+ Advanced Breast Cancer (NCT04224272) | Jazz Pharmaceuticals | 2020-06-10 |
Track HER2+/HR+ Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.